{"id":"placebo-to-alogliptin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL376359","moleculeType":"Small molecule","molecularWeight":"339.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alogliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to increased insulin secretion and decreased glucagon secretion in a glucose-dependent manner, resulting in improved glycemic control without causing hypoglycemia.","oneSentence":"Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:38.851Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07093476","phase":"PHASE3","title":"Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-07-18","conditions":"T2DM, Diabete Type 2, DM","enrollment":171},{"nctId":"NCT02068443","phase":"PHASE3","title":"Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Type 2 Diabetes Mellitus","enrollment":374},{"nctId":"NCT01686711","phase":"PHASE4","title":"A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-09","conditions":"Diabetes Mellitus","enrollment":207},{"nctId":"NCT05782192","phase":"PHASE3","title":"SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2019-06-13","conditions":"Diabetes Mellitus, Type 2","enrollment":458},{"nctId":"NCT02856113","phase":"PHASE3","title":"Phase 3 Alogliptin Pediatric Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-10-14","conditions":"Diabetes Mellitus, Type 2","enrollment":152},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT01890122","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-09","conditions":"Diabetes Mellitus","enrollment":647},{"nctId":"NCT00968708","phase":"PHASE3","title":"Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2, Acute Coronary Syndrome","enrollment":5380},{"nctId":"NCT00655863","phase":"PHASE3","title":"Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":"Diabetes Mellitus","enrollment":71},{"nctId":"NCT00707993","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Diabetes Mellitus","enrollment":441},{"nctId":"NCT00328627","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1554},{"nctId":"NCT00432276","phase":"PHASE3","title":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":803},{"nctId":"NCT00395512","phase":"PHASE3","title":"Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-11","conditions":"Diabetes Mellitus","enrollment":655},{"nctId":"NCT01023581","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":784},{"nctId":"NCT01289119","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01391663","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-07","conditions":"Pharmacokinetics and Pharmacodynamics","enrollment":48},{"nctId":"NCT00763347","phase":"PHASE2","title":"Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-11","conditions":"Diabetes Mellitus","enrollment":82},{"nctId":"NCT01263483","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Type 2 Diabetes Mellitus","enrollment":230},{"nctId":"NCT00286494","phase":"PHASE3","title":"Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-02","conditions":"Diabetes Mellitus","enrollment":493},{"nctId":"NCT01263470","phase":"PHASE2","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01318083","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT00286455","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-02","conditions":"Diabetes Mellitus","enrollment":329},{"nctId":"NCT00286442","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-03","conditions":"Diabetes Mellitus","enrollment":527},{"nctId":"NCT01318109","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":288},{"nctId":"NCT00286468","phase":"PHASE3","title":"Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-04","conditions":"Diabetes Mellitus","enrollment":500},{"nctId":"NCT00755846","phase":"PHASE2","title":"Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-03","conditions":"Diabetes Mellitus","enrollment":265},{"nctId":"NCT01318070","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-11","conditions":"Type 2 Diabetes Mellitus","enrollment":339},{"nctId":"NCT00286429","phase":"PHASE3","title":"Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-02","conditions":"Diabetes Mellitus","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":121,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to alogliptin","genericName":"Placebo to alogliptin","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}